Decision

Regulatory approval of COVID-19 Vaccine Valneva

Information for healthcare professionals and the public about the COVID-19 Vaccine Valneva

From:
Medicines and Healthcare products Regulatory Agency
Published
14 April 2022
Last updated
13 July 2022 — See all updates

Documents

Summary of Product Characteristics for COVID-19 Vaccine Valneva

Summary of Product Characteristics for COVID-19 Vaccine Valneva

PDF, 197 KB, 9 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Patient Information Leaflet for COVID-19 Vaccine Valneva

Patient Information Leaflet for COVID-19 Vaccine Valneva

PDF, 116 KB, 6 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Public Assessment Report for COVID-19 Vaccine Valneva

PDF, 895 KB, 31 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

Information about COVID-19 Vaccine Valneva suspension for injection, approved by the MHRA on 13 April 2022.

The Summary of Product Characteristics is a description of a medicinal product’s properties and the conditions attached to its use. It explains how to use and prescribe a medicine. It is used by healthcare professionals, such as doctors, nurses and pharmacists.

The Patient Information Leaflet provides information for patients on using the medicine safely. This is based on the Summary of Product Characteristics of the product.

The Conditional Marketing Authorisation (CMA) granted by the MHRA is valid in the United Kingdom (UK).

See further information in our press release.

Ingredients

The MHRA can confirm that COVID-19 Vaccine Valneva suspension for injection does not contain any components of animal origin.

A full list of ingredients for the qualitative and quantitative composition of the vaccine can be found at point 2 in the Summary of Product Characteristics for COVID-19 Vaccine Valneva suspension for injection.

A full list of ingredients for the excipient composition of the vaccine can be found at point 6.1 in the Summary of Product Characteristics for COVID-19 Vaccine Valneva suspension for injection.

A full list of ingredients for the qualitative and quantitative composition of the vaccine and a full list of the excipient composition of the vaccine can be found at point 6 in the Patient Information Leaflet for COVID-19 Vaccine Valneva suspension for injection.

Published 14 April 2022
Last updated 13 July 2022 + show all updates

  1. Added Public Assessment Report (PAR) PDF.

  2. First published.